CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 129 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2018. The put-call ratio across all filers is 0.57 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $28,000 | -78.1% | 55,800 | 0.0% | 0.00% | -100.0% |
| Q1 2018 | $128,000 | -26.9% | 55,800 | +15.1% | 0.00% | -50.0% |
| Q1 2016 | $175,000 | -78.3% | 48,500 | -3.2% | 0.00% | -77.8% |
| Q4 2015 | $808,000 | +54.5% | 50,100 | +1.0% | 0.01% | +50.0% |
| Q3 2015 | $523,000 | -56.0% | 49,600 | +5.3% | 0.01% | -57.1% |
| Q2 2015 | $1,188,000 | -6.1% | 47,100 | +3.7% | 0.01% | -12.5% |
| Q1 2015 | $1,265,000 | +45.2% | 45,400 | -5.2% | 0.02% | +45.5% |
| Q4 2014 | $871,000 | +28.5% | 47,900 | -8.4% | 0.01% | +22.2% |
| Q3 2014 | $678,000 | -19.0% | 52,300 | +1.9% | 0.01% | -30.8% |
| Q2 2014 | $837,000 | -4.3% | 51,300 | +3.6% | 0.01% | -7.1% |
| Q1 2014 | $875,000 | -18.9% | 49,500 | +7.4% | 0.01% | -22.2% |
| Q4 2013 | $1,079,000 | -32.6% | 46,100 | +2.0% | 0.02% | -35.7% |
| Q3 2013 | $1,601,000 | +140.0% | 45,200 | +2.7% | 0.03% | +115.4% |
| Q2 2013 | $667,000 | – | 44,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,000 | $3,096,000 | 100.00% |
| TSP Capital Management Group, LLC | 698,674 | $1,549,000 | 0.79% |
| Meditor Group Ltd | 6,312,700 | $2,847,000 | 0.61% |
| Telemetry Investments, L.L.C. | 186,200 | $84,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 1,270,500 | $573,000 | 0.03% |
| Benchmark Capital Advisors | 53,400 | $24,000 | 0.02% |
| BOENNING & SCATTERGOOD, INC. | 80,150 | $36,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 80,000 | $36,000 | 0.01% |
| Centiva Capital, LP | 121,720 | $55,000 | 0.01% |
| Overbrook Management Corp | 48,611 | $22,000 | 0.00% |